Hyperphosphataemia and drugs of ingredients of lenalidomide (a real world drug study)


Summary:

Hyperphosphataemia is found among people who take drugs with ingredients of lenalidomide, especially for people who are male, 60+ old , have been taking the drugs for < 1 month. This phase IV clinical study is created by eHealthMe based on reports of 423,289 people who have side effects when taking drugs with ingredients of lenalidomide from the FDA, and is updated regularly.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Lenalidomide, Revlimid.


On Jun, 01, 2026

423,289 people reported to have side effects when taking drugs with ingredients of lenalidomide.
Among them, 16 people (0.0%) have Hyperphosphataemia


What is Hyperphosphataemia?

Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood) is found to be associated with 432 drugs and 377 conditions by eHealthMe. Check the latest studies of Hyperphosphataemia.

Number of reports submitted per year:

Could drugs with ingredients of lenalidomide cause Hyperphosphataemia?

Time on drugs with ingredients of lenalidomide when people have Hyperphosphataemia *:

  • < 1 month: 85.71 %
  • 1 - 6 months: 14.29 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Hyperphosphataemia when taking drugs with ingredients of lenalidomide *:

  • female: 33.33 %
  • male: 66.67 %

Age of people who have Hyperphosphataemia when taking drugs with ingredients of lenalidomide *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 16.67 %
  • 60+: 83.33 %

Conditions people have *:

You may use this to check any potential undetected conditions.

  1. Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 3 people, 18.75%
  2. Chronic Lymphocytic Leukaemia Refractory (a cancer of blood cells lymphocytes that no longer responds favourably to treatment): 2 people, 12.50%
  3. Sleep Disorder: 1 person, 6.25%
  4. Hypoparathyroidism (inadequate secretion of parathyroid hormone resulting in abnormally low levels of calcium in the blood): 1 person, 6.25%
  5. Bone Loss: 1 person, 6.25%
  6. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 6.25%
  7. Anaemia (lack of blood): 1 person, 6.25%
  8. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 1 person, 6.25%

Other drugs people take *:

You may use this to check any potential interacting drugs.

  1. Thalidomide: 3 people, 18.75%
  2. Lansoprazole: 2 people, 12.50%
  3. Pomalyst: 2 people, 12.50%
  4. Dexamethasone: 2 people, 12.50%
  5. Omeprazole: 2 people, 12.50%
  6. Carfilzomib: 2 people, 12.50%
  7. Bortezomib: 2 people, 12.50%
  8. Bendamustine: 2 people, 12.50%
  9. Aspirin: 2 people, 12.50%
  10. Allopurinol: 2 people, 12.50%

Other side effects people have besides Hyperphosphataemia *:

You may use this to check any potential undetected side effects.

  1. Hyperuricaemia (level of uric acid in the blood that is abnormally high): 6 people, 37.50%
  2. Hypocalcaemia (levels of calcium in blood serum are abnormally low): 5 people, 31.25%
  3. Acute Kidney Failure: 5 people, 31.25%
  4. Fatigue (feeling of tiredness): 5 people, 31.25%
  5. Abdominal Pain: 5 people, 31.25%
  6. Tumor Lysis Syndrome: 5 people, 31.25%
  7. Thrombocytopenia (decrease of platelets in blood): 4 people, 25.00%
  8. Tumor Flare: 4 people, 25.00%
  9. Heart Attack: 4 people, 25.00%
  10. Weakness: 4 people, 25.00%

* Approximation only. Some reports may have incomplete information.


How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies

Drugs with ingredients of lenalidomide, their effectiveness, alternatives and more:

How the study uses the data?

The study uses data from the FDA. It is based on lenalidomide. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: